Long-term outcomes of juvenile-onset mycosis fungoides and lymphomatoid papulosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to follow up with participants diagnosed with juvenile-onset mycosis fungoides (jMF) and lymphomatoid papulosis (lyp) to assess their long-term health outcomes. The primary objective is to evaluate metrics such as overall survival rates over 5 and 10 years, as well as overall disease activity. Additionally, the study will gather information on treatments received and any associated comorbidities. Participants will include those diagnosed before the age of 20, with parents providing information for those under 18.

Why it matters

Who can join: the full rules

Inclusion Criteria:

-To be eligible, participants had to be diagnosed with jMF or lyp before age 20. In the case of participants below the age of 18, parents and not the children will be contacted for participation (children are exempt from participation as their parents may answer our study questions).

Exclusion Criteria:

-Participants older than 20 years of age at diagnosis

Where it's running

• MD Anderson Cancer Center
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Julia Dai, MD — M.D. Anderson Cancer Center
• Study coordinator: Julia Dai, MD
• Email: jdai6@mdanderson.org
• Phone: (713) 515-7961

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Poteligeo (mogamulizumab) for adults with mycosis fungoides or Sézary syndrome

  This project will try Poteligeo (mogamulizumab) in adults with mycosis fungoides or Sézary syndrome who have had at least one prior systemic therapy to see how safe and effective it is in routine care in Korea.

  Recruiting at 5 sites Kyowa Kirin Co., Ltd. · Busan, Busan Metropolitan City and 5 other locations · NCT07132567

• Golidocitnib treatment for relapsed indolent T/NK-cell lymphomas

  This study is testing if a new oral medication called Golidocitnib can help people with relapsed indolent T/NK-cell lymphomas feel better after other treatments haven't worked.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT06716658

• Using Riluzole to Help Breast Cancer Survivors with Cognitive Issues

  This study is testing if the medication riluzole can help breast cancer survivors who are having trouble with thinking and memory feel better.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06580002

• Using a modified virus to treat patients with T-cell lymphoma

  This study is testing a modified virus combined with immunotherapy to see if it can safely treat patients with different types of T-cell lymphoma.

  Recruiting at 2 sites Phase 1 Mayo Clinic · Scottsdale, Arizona and 1 other locations · NCT06508463

• Registry for individuals with T-cell lymphoma

  This study is gathering information from people with T-cell lymphoma to help researchers learn more about the disease and improve treatments.

  Recruiting at 6 sites Memorial Sloan Kettering Cancer Center · Duarte, California and 25 other locations · NCT05978141

• Combining a topical treatment with radiation for skin lymphoma

  This study is testing if using a skin cream along with radiation can help patients with a type of skin lymphoma that hasn't improved with regular treatments.

  Recruiting Early Phase 1 Northwestern University · Chicago, Illinois · NCT05838599

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.